Table 1 Demographics of study patients
From: Anti-TNF agents and potential effects on male fertility: are men being counseled?
Adalimumab | Etanercept | Infliximab | Golimumab | Certolizumab | Total | |
|---|---|---|---|---|---|---|
Number of patients | 600 | 161 | 219 | 8 | 22 | 1010 |
Age (years) | 32.8 ± 7.5 | 33.0 ± 6.9 | 30.9 ± 7.4 | 33.9 ± 7.5 | 31.8 ± 7.1 | 32.4 ± 7.5 |
Duration of treatment (days) | 799 ± 700 | 958 ± 878 | 853 ± 850 | 794 ± 725 | 669 ± 466 | 832 ± 806 |
Race | n % | n % | n % | n % | n % | n % |
American Indian | 1 (0.17) | 0 (0.00) | 2 (0.91) | 0 (0.00) | 0 (0.00) | 3 (0.30) |
Asian | 16 (2.67) | 5 (3.11) | 9 (4.10) | 0 (0.00) | 0 (0.00) | 30 (2.97) |
Black | 29 (4.83) | 4 (2.48) | 27 (12.32) | 0 (0.00) | 0 (0.00) | 60 (5.94) |
Hispanic | 1 (0.17) | 1 (0.62) | 2 (0.91) | 0 (0.00) | 0 (0.00) | 4 (0.40) |
Pacific Islander | 1 (0.17) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1 (0.01) |
White | 404 (67.33) | 99 (61.5) | 153 (69.86) | 8 (100) | 19 (86.36) | 683 (67.62) |
Declined | 78 (13.00) | 36 (22.4) | 9 (4.10) | 0 (0.00) | 0 (0.00) | 123 (12.18) |
Other | 70 (11.67) | 16 (9.94) | 17 (7.76) | 0 (0.00) | 3 (13.64) | 106 (10.50) |
Ethnicity | n % | n % | n % | n % | n % | n % |
Hispanic | 29 (4.83) | 10 (6.21) | 13 (5.93) | 0 (0.00) | 0 (0.00) | 52 (5.15) |
Not Hispanic/Latino | 465 (77.50) | 103 (63.98) | 177 (80.82) | 8 (100) | 19 (86.36) | 772 (76.44) |
Declined | 106 (17.67) | 48 (29.81) | 29 (13.24) | 0 (0.00) | 3 (13.64) | 186 (18.41) |
Marital Status | n % | n % | n % | n % | n % | n % |
Single | 342 (57.00) | 77 (47.83) | 153 (69.86) | 6 (75.00) | 13 (59.09) | 591 (58.51) |
Married | 205 (34.17) | 71 (44.10) | 64 (29.22) | 2 (25.00) | 9 (40.91) | 351 (34.75) |
Divorced | 4 (0.67) | 3 (1.86) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 7 (0.69) |
Other | 49 (8.17) | 10 (6.21) | 2 (0.91) | 0 (0.00) | 0 (0.00) | 61 (6.04) |
Diagnosis | n % | n % | n % | n % | n % | n % |
Ankylosing spondylitis | 61 (10.16) | 42 (26.09) | 7 (3.19) | 0 (0.00) | 1 (4.55) | 111 (10.99) |
Behcet’s | 2 (0.33) | 0 (0.00) | 1 (0.46) | 0 (0.00) | 0 (0.00) | 3 (0.29) |
Blau Syndrome | 2 (0.33) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 2 (0.20) |
Crohn’s | 107 (17.83) | 0 (0.00) | 90 (41.09) | 3 (37.50) | 13 (59.09) | 213 (21.10) |
Hidradenitis suppurativa | 25 (4.17) | 1 (0.62) | 1 (0.46) | 0 (0.00) | 0 (0.00) | 27 (2.67) |
Psoriasis ± arthritis | 256 (42.67) | 83 (51.55) | 11 (5.02) | 2 (25.00) | 2 (9.09) | 354 (35.05) |
Rheumatoid arthritis | 24 (4.00) | 20 (12.42) | 18 (8.22) | 0 (0.00) | 1 (4.55) | 63 (6.24) |
Sarcoidosis | 2 (0.33) | 0 (0.00) | 12 (5.48) | 0 (0.00) | 0 (0.00) | 14 (1.39) |
Seronegative arthritis | 28 (4.67) | 11 (6.83) | 0 (0.00) | 0 (0.00) | 1 (4.55) | 40 (3.96) |
Sjogren’s | 1 (0.17) | 2 (1.24) | 2 (0.91) | 0 (0.00) | 0 (0.00) | 5 (0.49) |
Ulcerative Colitis | 92 (15.33) | 2 (1.24) | 77 (35.16) | 3 (37.50) | 4 (18.18) | 178 (17.62) |